AMPK: Mediating the metabolic effects of salicylate-based drugs?

Trends in Endocrinology and Metabolism

Volumn 24, Issue 10, 2013, Pages 481-487

  Steinberg, Gregory R ^a   Dandapani, Madhumita ^b   Hardie, D Grahame ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

AMPK; Aspirin; Cancer; Diabetes; Inflammation; Salicylate

Indexed keywords

6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROSTAGLANDIN SYNTHASE; SALICYLIC ACID; SALSALATE;

ANTIINFLAMMATORY ACTIVITY; BLOOD CLOTTING; CELL METABOLISM; CHEMOPROPHYLAXIS; DRUG ABSORPTION; DRUG BINDING SITE; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; HUMAN; INSULIN RESISTANCE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REVIEW; RHEUMATIC FEVER; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION;

AMPK; ASPIRIN; CANCER; DIABETES; INFLAMMATION; SALICYLATE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTI-INFLAMMATORY AGENTS; DIABETES MELLITUS; ENZYME ACTIVATION; HUMANS; NEOPLASMS; SALICYLATES;

EID: 84884414016     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2013.06.002     Document Type: Review

References (60)

1. Vlot A.C., et al. Salicylic acid, a multifaceted hormone to combat disease. Annu. Rev. Phytopathol. 2009, 47:177-206.
2. Higgs G.A., et al. Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and antiinflammatory activity. Proc. Natl. Acad. Sci. U.S.A. 1987, 84:1417-1420.
3. Hawley S.A., et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science 2012, 336:918-922.
4. Din F.V., et al. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology 2012, 142:1504-1515.
5. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 1971, 231:232-235.
6. Vane J.R., et al. Cyclooxygenases 1 and 2. Ann. Rev. Pharm. Toxicol. 1998, 38:97-120.
7. Preston S.J., et al. Comparative analgesic and anti-inflammatory properties of sodium salicylate and acetylsalicylic acid (aspirin) in rheumatoid arthritis. Br. J. Clin. Pharmacol. 1989, 27:607-611.
8. Cronstein B.N., et al. Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:6377-6381.
9. Kopp E., Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994, 265:956-959.
10. Yin M.J., et al. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-beta. Nature 1998, 396:77-80.
11. International Centre for Kinase Profiling Kinase Inhibitor Database 2013, MRC Protein Phosphorylation and Ubiquitylation Unit. http://www.kinase-screen.mrc.ac.uk/kinase-inhibitors.
12. Shoelson S.E., et al. Inflammation and insulin resistance. J. Clin. Invest. 2006, 116:1793-1801.
13. Yuan M., et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001, 293:1673-1677.
14. Hundal R.S., et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J. Clin. Invest. 2002, 109:1321-1326.
15. Arkan M.C., et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat. Med. 2005, 11:191-198.
16. Goldfine A.B., et al. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia 2013, 56:714-723.
17. Fleischman A., et al. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 2008, 31:289-294.
18. Meex R.C., et al. Stimulation of human whole-body energy expenditure by salsalate is fueled by higher lipid oxidation under fasting conditions and by higher oxidative glucose disposal under insulin-stimulated conditions. J. Clin. Endocrinol. Metab. 2011, 96:1415-1423.
19. Vik-Mo H., Mjos O.D. Mechanisms for inhibition of free fatty acid mobilization by nicotinic acid and sodium salicylate in canine subcutaneous adipose tissue in situ. Scand. J. Clin. Lab. Invest. 1978, 38:209-216.
20. Beynen A.C., et al. Inhibition of hepatic lipogenesis by salicylate. Toxicology 1982, 24:33-43.
21. Steinberg G.R., Kemp B.E. AMPK in health and disease. Physiol. Rev. 2009, 89:1025-1078.
22. Hardie D.G., et al. AMP-activated protein kinase: a target for drugs both ancient and modern. Chem. Biol. 2012, 19:1222-1236.
23. Hawley S.A., et al. Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2003, 2:28.
24. Sakamoto K., et al. Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR. Am. J. Physiol. Endocrinol. Metab. 2004, 287:E310-E317.
25. Lizcano J.M., et al. LKB1 is a master kinase that activates 13 protein kinases of the AMPK subfamily, including the MARK/PAR-1 kinases. EMBO J. 2004, 23:833-843.
26. Oakhill J.S., et al. AMPK is a direct adenylate charge-regulated protein kinase. Science 2011, 332:1433-1435.
27. Xiao B., et al. Structure of mammalian AMPK and its regulation by ADP. Nature 2011, 472:230-233.
28. Hawley S.A., et al. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab. 2010, 11:554-565.
29. Goransson O., et al. Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J. Biol. Chem. 2007, 282:32549-32560.
30. Sanders M.J., et al. Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J. Biol. Chem. 2007, 282:32539-32548.
31. Scott J.W., et al. Thienopyridone drugs are selective activators of AMP-activated protein kinase beta1-containing complexes. Chem. Biol. 2008, 15:1220-1230.
32. Faubert B., et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab. 2012, 17:113-124.
33. Daval M., et al. Anti-lipolytic action of AMP-activated protein kinase in rodent adipocytes. J. Biol. Chem. 2005, 280:25250-25257.
34. Garton A.J., et al. Phosphorylation of bovine hormone-sensitive lipase by the AMP-activated protein kinase. A possible antilipolytic mechanism. Eur. J. Biochem. 1989, 179:249-254.
35. Salminen A., et al. AMP-activated protein kinase inhibits NF-kappaB signaling and inflammation: impact on healthspan and lifespan. J. Mol. Med. 2011, 89:667-676.
36. Green C.J., et al. Counter-modulation of fatty acid-induced pro-inflammatory nuclear factor kappaB signalling in rat skeletal muscle cells by AMP-activated protein kinase. Biochem. J. 2011, 435:463-474.
37. O'Neill L.A., Hardie D.G. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature 2013, 493:346-355.
38. Everts B., et al. Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells. Blood 2012, 120:1422-1431.
39. Krawczyk C.M., et al. Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood 2010, 115:4742-4749.
40. Haschemi A., et al. The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism. Cell Metab. 2012, 15:813-826.
41. Sag D., et al. Adenosine 5'-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J. Immunol. 2008, 181:8633-8641.
42. Yang Z., et al. Macrophage α1-AMP-activated protein kinase (α1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J. Biol. Chem. 2010, 285:19051-19059.
43. Galic S., et al. Hematopoietic AMPK beta1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity. J. Clin. Invest. 2011, 121:4903-4915.
44. 2+ in T lymphocytes. J. Exp. Med. 2006, 203:1665-1670.
45. MacIver N.J., et al. The liver kinase B1 is a central regulator of T cell development, activation, and metabolism. J. Immunol. 2011, 187:4187-4198.
46. Rolf J., et al. AMPKalpha1: a glucose sensor that controls CD8 T-cell memory. Eur. J. Immunol. 2013, 43:889-896.
47. Pearce E.L., et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 2009, 460:103-107.
48. Cuzick J., et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009, 10:501-507.
49. Rothwell P.M., et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011, 377:31-41.
50. Oshima M., et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996, 87:803-809.
51. Gamba C.A., et al. Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: the Women's Health Initiative. Cancer 2013, 119:1562-1569.
52. Cook N.R., et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005, 294:47-55.
53. Veitonmaki T., et al. Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. Eur. J. Cancer 2013, 49:938-945.
54. Shebl F.M., et al. Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO study. Br. J. Cancer 2012, 107:207-214.
55. Soranna D., et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 2012, 17:813-822.
56. Min/+ mice. Cancer Sci. 2008, 99:2136-2141.
57. Jeffreys D. Aspirin: The Remarkable Story of a Wonder Drug 2004, Bloomsbury Publishing.
58. Warburg O., et al. Uber den Stoffwechsel der Tumoren. Biochem. Z 1924, 152:319-344.
59. Pollard P.J., et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum. Mol. Genet. 2005, 14:2231-2239.
60. Young E.T., et al. Multiple pathways are co-regulated by the protein kinase Snf1 and the transcription factors Adr1 and Cat8. J. Biol. Chem. 2003, 278:26146-26158.